NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Lung Cancer Early Molecular Assessment Trial

UnknownN/A

Sponsor: The Netherlands Cancer Institute

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Liquid (blood) biopsies and tumor biopsy (optional)

Countries: Netherlands

The investigators hypothesize that an early molecular profiling, that includes both tissue and blood-bases analysis, for all NSCLC patients, including stage I-III, will increase diagnostic efficiency. When molecular profiles are available at an earlier stage of disease, more patients will benefit from personalized therapy once needed. This will result in both a better quality of life and outcome.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Suspicion of lung carcinoma or established NSCLC but awaiting start of definitive treatment
* Written informed consent to undergo diagnostic procedure and molecular analysis of the disease.

Exclusion Criteria:

* Not motivated to receive any treatment at any point in time. Patients who consider undergoing treatment in the future are eligible.

Locations (1)

Amsterdam, North Holland, Netherlands